

ARE YOU ELIGIBLE FOR BIOMARKER TESTING AT NO COST?

Approximately **47%** of people diagnosed with **advanced or metastatic non-small cell lung cancer (NSCLC)** have an actionable biomarker and may benefit from targeted therapy¹⁻¹⁰



If your lung cancer is driven by a biomarker, there may be additional treatment options available to you

- When people with lung cancer are not tested for actionable biomarkers, they may be missing out on the benefits of therapies that target the specific drivers of their cancer
- Some people may not receive comprehensive biomarker testing due to concerns about cost. Comprehensive biomarker testing can be expensive depending on insurance coverage, and some people may not have the ability to pay for this type of testing even with financial assistance



Through the Lilly Lung Cancer NGS Program, eligible people can receive comprehensive biomarker testing at **no cost**



To qualify, you need to meet all of the following criteria:

- ✓ You have advanced or metastatic NSCLC
- ✓ You currently live and receive treatment in the United States or a US territory (including Puerto Rico, Guam, and the Marshall Islands)
- ✓ You do not have a known molecular biomarker from a prior test
- ✓ You have not had prior comprehensive biomarker testing
- ✓ You have not previously been tested under this Program

Talk to your doctor* and find out if you're eligible for the Lilly Lung Cancer NGS Program—at no cost to you.

*For more information about this Program, have your doctor contact Tempus at **800-739-4137 Option 1**, email support@tempus.com, or visit tempus.com/LillyLungProgram.



TEMPUS



What is a biomarker?

- A biomarker is any molecule that can be measured in your tissue, blood, or other bodily fluids
- Biomarkers may reveal the specifics of a person's cancer, as well as how well the body may respond to certain types of treatment
- There are 2 types of biomarkers commonly used to tailor treatment for NSCLC:
 - Driver alterations: changes in your DNA or RNA that can cause your cancer to grow
 - Immunotherapy biomarkers: biomarkers that can show how the cancer interacts with your immune system

Testing for these biomarkers can help determine whether certain types of targeted therapies or immunotherapies may work well to treat your cancer.



What is comprehensive biomarker testing?

- Comprehensive biomarker testing in NSCLC includes testing for all recommended actionable biomarkers based on clinical guidelines to help doctors understand more about a person's specific type of cancer
 - Comprehensive biomarker testing can be performed using either a tissue biopsy or in some cases a blood test
 - After the tumor tissue or blood sample is collected, it is sent to a lab for testing
- Next-generation sequencing (NGS) is a method for identifying actionable biomarkers in a single test, and is the type of comprehensive biomarker testing performed in this Program



How do doctors use comprehensive biomarker testing results?

- Biomarkers identified through comprehensive biomarker testing can be used to determine the appropriate treatment approach for your NSCLC, including the prescription of currently approved therapies or participation in an active clinical trial

With the advancements in cancer treatments, it is important to speak with your doctor about testing for all actionable biomarkers.

This content was adapted with permission from [LUNGeivity Foundation](#).

You will not be billed for this test.

DNA=deoxyribonucleic acid; RNA=ribonucleic acid.

References: 1. Fernandes MGO, Jacob M, Martins N, et al. Targeted gene next-generation sequencing panel in patients with advanced lung adenocarcinoma: paving the way for clinical implementation. *Cancers (Basel)*. 2019;11(9):1229. 2. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. *Lancet*. 2017;389:299-311. 3. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in *RET* fusion-positive non-small-cell lung cancer. *N Engl J Med*. 2020;383(9):813-824. 4. Amatu A, Sartore-Bianchi A, Siena S. *NTRK* gene fusions as novel targets of cancer therapy across multiple tumour types. *ESMO Open*. 2016;1(2):e000023. doi:10.1136/esmoopen-2015-000023. 5. Vansteenkiste JF, Van De Kerkhove C, Wauters E, et al. Capmatinib for the treatment of non-small cell lung cancer. *Expert Rev Anticancer Ther*. 2019;19(8):659-671. 6. Drilon A, Hu ZI, Lai GGY, et al. Targeting *RET*-driven cancers: lessons from evolving preclinical and clinical landscapes. *Nat Rev Clin Oncol*. 2018;15(3):151-167. 7. FDA approves first targeted therapy to treat aggressive form of lung cancer. News release. FDA. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-cancer>. May 6, 2020. Accessed May 21, 2020. 8. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated *BRAF*(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol*. 2016;17(7):984-993. 9. FDA approves first targeted therapy for subset of non-small cell lung cancer. News release. FDA. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-subset-non-small-cell-lung-cancer>. May 21, 2021. Accessed June 30, 2021. 10. FDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy. News release. FDA. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug>. May 28, 2021. Accessed June 17, 2021.

